blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2513147

EP2513147 - NOVEL ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.05.2017
Database last updated on 05.10.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
SANOFI
54, rue La Boétie
75008 Paris / FR
[2016/29]
Former [2012/43]For all designated states
SANOFI
54, rue de la Boétie
75008 Paris / FR
Inventor(s)01 / BAURIN, Nicolas
c/o Sanofi-Aventis Département Brevets
174 avenue de France
75013 Paris / FR
02 / BLANCHE, Francis
c/o Sanofi-Aventis Département Brevets
174 avenue de France
75013 Paris / FR
03 / CAMERON, Béatrice
c/o Sanofi-Aventis Département Brevets
174 avenue de France
75013 Paris / FR
04 / CORVEY, Carsten
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
05 / DABDOUBI, Tarik
c/o Sanofi-Aventis Département Brevets
174 avenue de France
75013 Paris / FR
06 / ENGEL, Christian
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
07 / FLORIAN, Peter
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
08 / FOCKEN, Ingo
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
09 / KROLL, Katja
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
10 / KRUIP, Jochen
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
11 / LANGE, Christian
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
12 / LANGER, Thomas
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
13 / LORENZ, Martin
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
14 / MIKOL, Vincent
c/o Sanofi-Aventis Département Brevets
174 avenue de France
75013 Paris / FR
15 / RAO, Ercole
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
16 / WONEROW, Peter
c/o Sanofi-Aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
 [2016/29]
Former [2012/43]01 / BAURIN, Nicolas
c/o sanofi-aventis Département Brevets
174 avenue de France
F-75013 Paris / FR
02 / BLANCHE, Francis
c/o sanofi-aventis Département Brevets
174 avenue de France
F-75013 Paris / FR
03 / CAMERON, Béatrice
c/o sanofi-aventis Département Brevets
174 avenue de France
F-75013 Paris / FR
04 / CORVEY, Carsten
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
05 / DABDOUBI, Tarik
c/o sanofi-aventis Département Brevets
174 avenue de France
F-75013 Paris / FR
06 / ENGEL, Christian
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
07 / FLORIAN, Peter
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
08 / FOCKEN, Ingo
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
09 / KROLL, Katja
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
10 / KRUIP, Jochen
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
11 / LANGE, Christian
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
12 / LANGER, Thomas
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
13 / LORENZ, Martin
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
14 / MIKOL, Vincent
c/o sanofi-aventis Département Brevets
174 avenue de France
F-75013 Paris / FR
15 / RAO, Ercole
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
16 / WONEROW, Peter
c/o sanofi-aventis Deutschland GmbH
Patent Department
65926 Frankfurt / DE
Former [2011/32]01 / BAURIN, Nicolas
c/o sanofi-aventis Département Brevets 174 avenue de France
F-75013 Paris / FR
02 / BLANCHE, Francis
c/o sanofi-aventis Département Brevets 174 avenue de France
F-75013 Paris / FR
03 / CAMERON, Béatrice
c/o sanofi-aventis Département Brevets 174 avenue de France
F-75013 Paris / FR
04 / CORVEY, Carsten
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
05 / DABDOUBI, Tarik
c/o sanofi-aventis Département Brevets 174 avenue de France
F-75013 Paris / FR
06 / ENGEL, Christian
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
07 / FLORIAN, Peter
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
08 / FOCKEN, Ingo
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
09 / KROLL, Katja
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
10 / KRUIP, Jochen
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
11 / LANGE, Christian
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
12 / LANGER, Thomas
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
13 / LORENZ, Martin
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
14 / MIKOL, Vincent
c/o sanofi-aventis Département Brevets 174 avenue de France
F-75013 Paris / FR
15 / RAO, Ercole
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
16 / WONEROW, Peter
c/o sanofi-aventis Deutschland GmbH Patent Department
65926 Frankfurt / DE
Representative(s)Zwicker, Jörk
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[N/P]
Former [2016/29]Zwicker, Jörk
ZSP Patentanwälte PartG mbB
Radlkoferstrasse 2
81373 München / DE
Former [2012/43]Martin-Touaux, Elsa, et al
Sanofi
Département Brevets
174 avenue de France
75013 Paris / FR
Application number, filing date10813028.717.12.2010
[2016/29]
WO2010IB55917
Priority number, dateEP2009030628318.12.2009         Original published format: EP 09306283
EP2010030566021.06.2010         Original published format: EP 10305660
EP2010030572101.07.2010         Original published format: EP 10305721
[2011/32]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011073954
Date:23.06.2011
Language:EN
[2011/25]
Type: A2 Application without search report 
No.:EP2513147
Date:24.10.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 23.06.2011 takes the place of the publication of the European patent application.
[2012/43]
Type: B1 Patent specification 
No.:EP2513147
Date:20.07.2016
Language:EN
[2016/29]
Search report(s)International search report - published on:EP08.03.2012
ClassificationIPC:C07K16/28, A61K39/00, C07K1/107
[2016/06]
CPC:
C07K16/2803 (EP,US); C07K16/28 (KR,US); A61K38/17 (KR);
A61K38/18 (KR); A61K39/395 (KR); A61K48/00 (KR);
A61K49/14 (KR); A61P37/00 (EP); A61P7/00 (EP);
A61P7/02 (EP); A61P9/00 (EP); A61P9/10 (EP);
C07K1/1075 (US); C07K14/435 (KR); C07K14/475 (KR);
C07K16/18 (KR); C07K16/22 (KR); C07K16/24 (KR);
A61K2039/505 (EP,US); C07K2317/24 (EP,US); C07K2317/33 (EP,US);
C07K2317/34 (EP,US); C07K2317/41 (EP,US); C07K2317/51 (US);
C07K2317/515 (US); C07K2317/55 (EP,US); C07K2317/565 (EP,US);
C07K2317/567 (EP,US); C07K2317/76 (EP,US); C07K2317/92 (EP,US) (-)
Former IPC [2011/32]C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/43]
Extension statesBA10.09.2012
ME10.09.2012
TitleGerman:NEUARTIGE ANTAGONISTENANTIKÖRPER UND IHRE FAB-FRAGMENTE GEGEN GPVI SOWIE VERWENDUNGEN DAVON[2012/43]
English:NOVEL ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF[2012/43]
French:NOUVEAUX ANTICORPS ANTAGONISTES ET LEURS FRAGMENTS FAB DIRIGÉS CONTRE GPVI, ET UTILISATIONS DE CEUX-CI[2012/43]
Entry into regional phase18.07.2012National basic fee paid 
10.09.2012Designation fee(s) paid 
10.09.2012Examination fee paid 
Examination procedure10.09.2012Examination requested  [2012/43]
08.05.2013Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
18.07.2013Amendment by applicant (claims and/or description)
04.11.2013Despatch of a communication from the examining division (Time limit: M06)
22.04.2014Reply to a communication from the examining division
08.07.2014Despatch of a communication from the examining division (Time limit: M04)
07.11.2014Reply to a communication from the examining division
20.02.2015Despatch of a communication from the examining division (Time limit: M02)
02.03.2015Reply to a communication from the examining division
09.02.2016Communication of intention to grant the patent
08.06.2016Fee for grant paid
08.06.2016Fee for publishing/printing paid
08.06.2016Receipt of the translation of the claim(s)
Divisional application(s)EP15164863.1  / EP2933269
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.11.2013
Opposition(s)21.04.2017No opposition filed within time limit [2017/26]
Request for further processing for:18.07.2013Request for further processing filed
18.07.2013Full payment received (date of receipt of payment)
Request granted
22.08.2013Decision despatched
Fees paidRenewal fee
11.12.2012Renewal fee patent year 03
12.12.2013Renewal fee patent year 04
11.12.2014Renewal fee patent year 05
10.12.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL20.07.2016
MK20.07.2016
RS20.07.2016
SM20.07.2016
NO20.10.2016
IS20.11.2016
[2018/46]
Former [2018/30]MK20.07.2016
RS20.07.2016
SM20.07.2016
NO20.10.2016
IS20.11.2016
Former [2017/37]RS20.07.2016
SM20.07.2016
NO20.10.2016
IS20.11.2016
Former [2017/11]RS20.07.2016
NO20.10.2016
IS20.11.2016
Former [2017/09]NO20.10.2016
Cited inInternational search[I]WO0100810  (MILLENNIUM PHARM INC [US]) [I] 1-6,9-13,15 * the whole document *;
 [I]EP1224942  (NIESWANDT BERNHARD [DE]) [I] 1-6,9-13,15 * the whole document *;
 [I]EP1228768  (NIESWANDT BERNHARD [DE]) [I] 1-6,9-13,15 * the whole document *;
 [I]WO02080968  (MILLENNIUM PHARM INC [US]) [I] 1-6,9-13,15 * the whole document *;
 [I]WO03054020  (UNIV CAMBRIDGE TECH [GB], et al) [I] 1-6,9-13,15 * the whole document *;
 [I]EP1369128  (PROCORDE GMBH [DE]) [I] 1-6,9-13,15 * the whole document *;
 [I]EP1538165  (PROCORDE GMBH [DE], et al) [I] 1-6,9-13,15 * the whole document *;
 [XI]WO2005090407  (IMCLONE SYSTEMS INC [US], et al) [X] 7,8 * The whole document, in particular SEQ ID NO:17-19 *[I] 9-13;
 [I]WO2005111083  (OTSUKA PHARMA CO LTD [JP], et al) [I] 1-6,9-13,15 * The whole document, in particular; paragraph [0122]; table 7 *;
 [I]EP1647596  (MOCHIDA PHARM CO LTD [JP]) [I] 1-6,9-13,15 * The whole document, in particular;; figure 5 *;
 [I]WO2006061650  (TRIGEN GMBH [DE], et al) [I] 1-6,9-13,15 * the whole document *;
 [I]WO2006131512  (TRIGEN GMBH [DE], et al) [I] 1-6,9-13,15 * the whole document *;
 [I]WO2007091719  (MOCHIDA PHARM CO LTD [JP], et al) [I] 1-6,9-13,15 * the whole document *;
 [I]EP1876240  (MOCHIDA PHARM CO LTD [JP]) [I] 1-6,9-13,15 * The whole document, in particular;; table 2 *;
 [I]EP1916259  (INST NAT SANTE RECH MED [FR]) [I] 1-6,9-13,15 * The whole document, in particular;; figure 8 *;
 [I]EP2000802  (MOCHIDA PHARM CO LTD [JP]) [I] 1-6,9-13,15 * the whole document *;
 [I]US2009041783  (TAKAYAMA HIROSHI [JP], et al) [I] 1-6,9-13,15 * the whole document *;
 [I]WO2009058326  (OTSUKA PHARMA CO LTD [JP], et al) [I] 1-6,9-13,15 * The whole document, in particular; paragraph [0009] *;
 [I]  - NIESWANDT BERNHARD ET AL, "Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, UNITED STATES, (20010219), vol. 193, no. 4, ISSN 0022-1007, pages 459 - 469, XP002174652 [I] 1-6,9-13,15 * the whole document *

DOI:   http://dx.doi.org/10.1084/jem.193.4.459
 [I]  - SCHULTE VALERIE ET AL, "Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, HIGHWIRE PRESS, PHILADELPHIA, PA, US, (20060701), vol. 26, no. 7, ISSN 1524-4636, pages 1640 - 1647, XP002486445 [I] 1-6,9-13,15 * the whole document *

DOI:   http://dx.doi.org/10.1161/.ATV.0000225697.98093.ed
 [XI]  - ASHUTOSH TIWARI ET AL, "Generation and Characterization of High Affinity Humanized Fab Against Hepatitis B Surface Antigen", MOLECULAR BIOTECHNOLOGY, (20090901), vol. 43, no. 1, doi:10.1007/s12033-009-9165-9, ISSN 1073-6085, pages 29 - 40, XP055016065 [X] 7,8 * the whole document * [I] 9-14

DOI:   http://dx.doi.org/10.1007/s12033-009-9165-9
Examination   - Andreas Plückthun, "Strategies for the expression of antibody fragments in Escherichia coli", Methods, (19910401), vol. 2, no. 2, doi:10.1016/S1046-2023(05)80208-7, ISSN 1046-2023, pages 88 - 96, XP055085444

DOI:   http://dx.doi.org/10.1016/S1046-2023(05)80208-7
by applicantUS6448380
 WO2009032661
    - NIESWANDT B; WATSON SP, BLOOD, (20030715), vol. 102, no. 2, pages 449 - 61
    - LOCKYER S ET AL., THROMB RES., (2006), vol. 118, no. 3, pages 371 - 80
    - KARLSSON R; LARSSON A, J. MOL. BIOL., (2004), vol. 248, pages 389 - 415
    - KORMEIER ET AL., J. IMMUNOL., (1968), vol. 100, no. 3, pages 612 - 21
    - PERSSELIN; STEVENS, J. CLIN.LNVEST., (1985), vol. 76, pages 723 - 30
    - BIGALKE B. ET AL., SEMIN THROMB HEMOST., (200703), vol. 33, no. 2, pages 179 - 84
    - A. H. HORWITZ ET AL., PNAS, (198811), vol. 85, no. 22, pages 8678 - 82
    - CHIBA Y; JIGAMI Y, CURR OPIN CHEM BIOL., (200712), vol. 11, no. 6, pages 670 - 6
    - KILPATRICK ET AL., HYBRIDOMA, (1997), vol. 16, page 381389
    - CANZIANI ET AL., ANAL. BIOCHEM., (2004), vol. 325, pages 301 - 307
    - YOUNG L.; DONG Q., NUCL. ACIDS RES., (2004), vol. 32, no. 7, page E59
    - DUROCHER ET AL., NUCL. ACIDS RES., (2002), vol. 30, no. 2, page E9
    - AI-LAZIKANI, J. MOL. BIOL., (1997), vol. 273, pages 927 - 948
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.